Form 4: Lyra Therapeutics CEO Sells Shares for Tax Obligations

Lyra Therapeutics President & CEO Maria Palasis sold 1,702 shares of common stock to cover tax obligations related to RSU vesting, as per a pre-arranged 10b5-1 plan.

Summary

• Maria Palasis, President & CEO and Director of Lyra Therapeutics, Inc., reported a sale of common stock.
• The transaction involved the disposition of 1,702 shares of Lyra Therapeutics common stock.
• The shares were sold at a price of $3.364 per share.
• The sale occurred on January 6, 2026.
• The purpose of the sale was to cover tax obligations arising from the vesting of restricted stock units (RSUs).
• This transaction was executed under a mandatory Rule 10b5-1 trading instruction, established on January 1, 2025.
• Following the transaction, Maria Palasis beneficially owns 1,096,733 shares of common stock.

Sentiment

Score: 5

Explanation: A routine insider sale to cover tax liabilities from RSU vesting, executed under a 10b5-1 plan, is generally neutral in sentiment as it is not indicative of management's view on the company's future prospects.

Future Outlook

NA

Management Comments

• Shares were sold to cover taxes upon the vesting of restricted stock units ("RSUs") pursuant to a mandatory Rule 10b5-1 trading instruction in the award agreement adopted by the Reporting Person on January 1, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Industry Context

This is a routine insider transaction (Form 4) related to tax obligations upon RSU vesting, common across all industries for executives receiving equity compensation. It does not reflect specific industry trends or competitive positioning.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, pre-scheduled transaction for tax purposes, not indicative of a change in management's confidence.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The reported transaction is a routine, pre-scheduled sale of shares by an executive to cover tax obligations upon the vesting of restricted stock units. Such transactions, especially those executed under a Rule 10b5-1 plan, are generally not considered indicative of management's sentiment regarding the company's future performance and typically do not warrant a change in investment recommendation. Investors should focus on the company's operational and financial performance rather than this administrative insider sale.

Keywords

Lyra Therapeutics, LYRA, Maria Palasis, Insider Trading, Form 4, Stock Sale, RSU Vesting, Tax Obligations, 10b5-1 Plan, Biotechnology